Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Livagen: Evidence Summary
Evidence summary for Livagen across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Livagen overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Liver protection | Tier D | 0 | No human trials exist; rodent studies report hepatocyte protection from toxins but remain unverified |
| Liver regeneration | Tier D | 0 | Animal data suggests hepatocyte proliferation effects but no human translation has been attempted |